Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease. Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.
$115M sweet spot round size
2020
$115M
from 3 investors over 1 rounds
Evommune raised $115M on December 1, 2024
Investors: Sectoral Asset Management, RA Capital Management and + 16 Other investors